C9orf72 BAC Mouse Model with Motor Deficits and Neurodegenerative Features of ALS/FTD

Neuron

Volumn 90, Issue 3, 2016, Pages 521-534

  Liu, Yuanjing ^a   Pattamatta, Amrutha ^a   Zu, Tao ^a   Reid, Tammy ^a   Bardhi, Olgert ^a   Borchelt, David R ^a,b   Yachnis, Anthony T ^b   Ranum, Laura P W ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ARTICLE; BIOACCUMULATION; BRAIN REGION; C9ORF72 GENE; CELL POPULATION; CONTROLLED STUDY; DISEASE MODEL; DNA FLANKING REGION; FEMALE; FRONTOTEMPORAL DEMENTIA; GENE; GENE EXPRESSION; HIPPOCAMPUS; MALE; MOTOR DYSFUNCTION; MOTOR NEURON DISEASE; MOUSE; MUSCLE DENERVATION; NERVE DEGENERATION; NONHUMAN; PARALYSIS; PHENOTYPE; PRIORITY JOURNAL; SURVIVAL RATE; TRANSCRIPTION REGULATION; TRANSGENIC MOUSE; UPREGULATION; ANIMAL; BRAIN; GENETICS; METABOLISM; MOTONEURON; MUTATION; PHYSIOLOGY;

C9ORF72 PROTEIN, MOUSE; DNA BINDING PROTEIN; GUANINE NUCLEOTIDE EXCHANGE FACTOR; REPETITIVE DNA;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; DNA REPEAT EXPANSION; DNA-BINDING PROTEINS; FRONTOTEMPORAL DEMENTIA; GUANINE NUCLEOTIDE EXCHANGE FACTORS; MICE, TRANSGENIC; MOTOR NEURONS; MUTATION;

EID: 84963958172     PISSN: 08966273     EISSN: 10974199     Source Type: Journal    
DOI: 10.1016/j.neuron.2016.04.005     Document Type: Article

References (54)

1. Al-Sarraj S., King A., Troakes C., Smith B., Maekawa S., Bodi I., Rogelj B., Al-Chalabi A., Hortobágyi T., Shaw C.E. p62 positive, TDP-43 negative, neuronal cytoplasmic and intranuclear inclusions in the cerebellum and hippocampus define the pathology of C9orf72-linked FTLD and MND/ALS. Acta Neuropathol. 2011, 122:691-702.
2. Ash P.E., Bieniek K.F., Gendron T.F., Caulfield T., Lin W.L., Dejesus-Hernandez M., van Blitterswijk M.M., Jansen-West K., Paul J.W., Rademakers R., et al. Unconventional translation of C9ORF72 GGGGCC expansion generates insoluble polypeptides specific to c9FTD/ALS. Neuron 2013, 77:639-646.
3. Bañez-Coronel M., Ayhan F., Tarabochia A.D., Zu T., Perez B.A., Tusi S.K., Pletnikova O., Borchelt D.R., Ross C.A., Margolis R.L., et al. RAN translation in Huntington disease. Neuron 2015, 88:667-677.
4. Batra R., Charizanis K., Swanson M.S. Partners in crime: bidirectional transcription in unstable microsatellite disease. Hum. Mol. Genet. 2010, 19(R1):R77-R82.
5. Chew J., Gendron T.F., Prudencio M., Sasaguri H., Zhang Y.J., Castanedes-Casey M., Lee C.W., Jansen-West K., Kurti A., Murray M.E., et al. Neurodegeneration. C9ORF72 repeat expansions in mice cause TDP-43 pathology, neuronal loss, and behavioral deficits. Science 2015, 348:1151-1154.
6. Cho D.H., Thienes C.P., Mahoney S.E., Analau E., Filippova G.N., Tapscott S.J. Antisense transcription and heterochromatin at the DM1 CTG repeats are constrained by CTCF. Mol. Cell 2005, 20:483-489.
7. Ciura S., Lattante S., Le Ber I., Latouche M., Tostivint H., Brice A., Kabashi E. Loss of function of C9orf72 causes motor deficits in a zebrafish model of amyotrophic lateral sclerosis. Ann. Neurol. 2013, 74:180-187.
8. Cleary J.D., Ranum L.P. Repeat-associated non-ATG (RAN) translation in neurological disease. Hum. Mol. Genet. 2013, 22(R1):R45-R51.
9. Cleary J.D., Ranum L.P. Repeat associated non-ATG (RAN) translation: new starts in microsatellite expansion disorders. Curr. Opin. Genet. Dev. 2014, 26:6-15.
10. Cooper-Knock J., Higginbottom A., Stopford M.J., Highley J.R., Ince P.G., Wharton S.B., Pickering-Brown S., Kirby J., Hautbergue G.M., Shaw P.J. Antisense RNA foci in the motor neurons of C9ORF72-ALS patients are associated with TDP-43 proteinopathy. Acta Neuropathol. 2015, 130:63-75.
11. Cruts M., Gijselinck I., Van Langenhove T., van der Zee J., Van Broeckhoven C. Current insights into the C9orf72 repeat expansion diseases of the FTLD/ALS spectrum. Trends Neurosci. 2013, 36:450-459.
12. DeJesus-Hernandez M., Mackenzie I.R., Boeve B.F., Boxer A.L., Baker M., Rutherford N.J., Nicholson A.M., Finch N.A., Flynn H., Adamson J., et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron 2011, 72:245-256.
13. Freibaum B.D., Lu Y., Lopez-Gonzalez R., Kim N.C., Almeida S., Lee K.H., Badders N., Valentine M., Miller B.L., Wong P.C., et al. GGGGCC repeat expansion in C9orf72 compromises nucleocytoplasmic transport. Nature 2015, 525:129-133.
14. Gendron T.F., van Blitterswijk M., Bieniek K.F., Daughrity L.M., Jiang J., Rush B.K., Pedraza O., Lucas J.A., Murray M.E., Desaro P., et al. Cerebellar c9RAN proteins associate with clinical and neuropathological characteristics of C9ORF72 repeat expansion carriers. Acta Neuropathol. 2015, 130:559-573.
15. Goodwin M., Swanson M.S. RNA-binding protein misregulation in microsatellite expansion disorders. Adv. Exp. Med. Biol. 2014, 825:353-388.
16. Hsiao K.K., Borchelt D.R., Olson K., Johannsdottir R., Kitt C., Yunis W., Xu S., Eckman C., Younkin S., Price D., et al. Age-related CNS disorder and early death in transgenic FVB/N mice overexpressing Alzheimer amyloid precursor proteins. Neuron 1995, 15:1203-1218.
17. Hu J., Liu J., Yu D., Chu Y., Corey D.R. Mechanism of allele-selective inhibition of huntingtin expression by duplex RNAs that target CAG repeats: function through the RNAi pathway. Nucleic Acids Res. 2012, 40:11270-11280.
18. Jovičić A., Mertens J., Boeynaems S., Bogaert E., Chai N., Yamada S.B., Paul J.W., Sun S., Herdy J.R., Bieri G., et al. Modifiers of C9orf72 dipeptide repeat toxicity connect nucleocytoplasmic transport defects to FTD/ALS. Nat. Neurosci. 2015, 18:1226-1229.
19. Keum S., Park J., Kim A., Park J., Kim K.K., Jeong J., Shin H.S. Variability in empathic fear response among 11 inbred strains of mice. Genes Brain Behav. 2016, 15:231-242.
20. Koppers M., Blokhuis A.M., Westeneng H.J., Terpstra M.L., Zundel C.A., Vieira de Sá R., Schellevis R.D., Waite A.J., Blake D.J., Veldink J.H., et al. C9orf72 ablation in mice does not cause motor neuron degeneration or motor deficits. Ann. Neurol. 2015, 78:426-438.
21. Kordasiewicz H.B., Stanek L.M., Wancewicz E.V., Mazur C., McAlonis M.M., Pytel K.A., Artates J.W., Weiss A., Cheng S.H., Shihabuddin L.S., et al. Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis. Neuron 2012, 74:1031-1044.
22. Kril J.J., Halliday G.M. Pathological staging of frontotemporal lobar degeneration. J. Mol. Neurosci. 2011, 45:379-383.
23. Kwon I., Xiang S., Kato M., Wu L., Theodoropoulos P., Wang T., Kim J., Yun J., Xie Y., McKnight S.L. Poly-dipeptides encoded by the C9orf72 repeats bind nucleoli, impede RNA biogenesis, and kill cells. Science 2014, 345:1139-1145.
24. Lagier-Tourenne C., Baughn M., Rigo F., Sun S., Liu P., Li H.R., Jiang J., Watt A.T., Chun S., Katz M., et al. Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration. Proc. Natl. Acad. Sci. USA 2013, 110:E4530-E4539.
25. Lashley T., Rohrer J.D., Mead S., Revesz T. Review: an update on clinical, genetic and pathological aspects of frontotemporal lobar degenerations. Neuropathol. Appl. Neurobiol. 2015, 41:858-881.
26. Ling S.C., Polymenidou M., Cleveland D.W. Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Neuron 2013, 79:416-438.
27. Mahoney C.J., Beck J., Rohrer J.D., Lashley T., Mok K., Shakespeare T., Yeatman T., Warrington E.K., Schott J.M., Fox N.C., et al. Frontotemporal dementia with the C9ORF72 hexanucleotide repeat expansion: clinical, neuroanatomical and neuropathological features. Brain 2012, 135:736-750.
28. McKhann G.M., Albert M.S., Grossman M., Miller B., Dickson D., Trojanowski J.Q. Clinical and pathological diagnosis of frontotemporal dementia: report of the Work Group on Frontotemporal Dementia and Pick's Disease. Arch. Neurol. 2001, 58:1803-1809. Work Group on Frontotemporal Dementia and Pick's Disease.
29. Miller B.H., Schultz L.E., Gulati A., Su A.I., Pletcher M.T. Phenotypic characterization of a genetically diverse panel of mice for behavioral despair and anxiety. PLoS ONE 2010, 5:e14458.
30. Milner L.C., Crabbe J.C. Three murine anxiety models: results from multiple inbred strain comparisons. Genes Brain Behav. 2008, 7:496-505.
31. Mizielinska S., Grönke S., Niccoli T., Ridler C.E., Clayton E.L., Devoy A., Moens T., Norona F.E., Woollacott I.O., Pietrzyk J., et al. C9orf72 repeat expansions cause neurodegeneration in Drosophila through arginine-rich proteins. Science 2014, 345:1192-1194.
32. Mori K., Weng S.M., Arzberger T., May S., Rentzsch K., Kremmer E., Schmid B., Kretzschmar H.A., Cruts M., Van Broeckhoven C., et al. The C9orf72 GGGGCC repeat is translated into aggregating dipeptide-repeat proteins in FTLD/ALS. Science 2013, 339:1335-1338.
33. Moseley M.L., Zu T., Ikeda Y., Gao W., Mosemiller A.K., Daughters R.S., Chen G., Weatherspoon M.R., Clark H.B., Ebner T.J., et al. Bidirectional expression of CUG and CAG expansion transcripts and intranuclear polyglutamine inclusions in spinocerebellar ataxia type 8. Nat. Genet. 2006, 38:758-769.
34. O'Rourke J.G., Bogdanik L., Muhammad A.K.M.G., Gendron T.F., Kim K.J., Austin A., Cady J., Liu E.Y., Zarrow J., Grant S., et al. C9orf72 BAC transgenic mice display typical pathologic features of ALS/FTD. Neuron 2015, 88:892-901.
35. Orr H.T., Zoghbi H.Y. Trinucleotide repeat disorders. Annu. Rev. Neurosci. 2007, 30:575-621.
36. Peters O.M., Cabrera G.T., Tran H., Gendron T.F., McKeon J.E., Metterville J., Weiss A., Wightman N., Salameh J., Kim J., et al. Human C9ORF72 hexanucleotide expansion reproduces RNA foci and dipeptide repeat proteins but not neurodegeneration in BAC transgenic mice. Neuron 2015, 88:902-909.
37. Pletnikova O., Sloane K.L., Renton A.E., Traynor B.J., Crain B.J., Reid T., Zu T., Ranum L.P., Troncoso J.C., Rabins P.V., Onyike C.U. Hippocampal sclerosis dementia with the C9ORF72 hexanucleotide repeat expansion. Neurobiol. Aging 2014, 35:2419.e17-2419.e21.
38. Ranum L.P., Cooper T.A. RNA-mediated neuromuscular disorders. Annu. Rev. Neurosci. 2006, 29:259-277.
39. Renton A.E., Majounie E., Waite A., Simón-Sánchez J., Rollinson S., Gibbs J.R., Schymick J.C., Laaksovirta H., van Swieten J.C., Myllykangas L., et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron 2011, 72:257-268. ITALSGEN Consortium.
40. Rowland L.P., Shneider N.A. Amyotrophic lateral sclerosis. N. Engl. J. Med. 2001, 344:1688-1700.
41. Seltman R.E., Matthews B.R. Frontotemporal lobar degeneration: epidemiology, pathology, diagnosis and management. CNS Drugs 2012, 26:841-870.
42. Sopher B.L., Ladd P.D., Pineda V.V., Libby R.T., Sunkin S.M., Hurley J.B., Thienes C.P., Gaasterland T., Filippova G.N., La Spada A.R. CTCF regulates ataxin-7 expression through promotion of a convergently transcribed, antisense noncoding RNA. Neuron 2011, 70:1071-1084.
43. Strong M.K., Southwell A.L., Yonan J.M., Hayden M.R., Macgregor G.R., Thompson L.M., Steward O. Age-dependent resistance to excitotoxicity in Htt CAG140 mice and the effect of strain background. J. Huntingtons Dis. 2012, 1:221-241.
44. Suzuki N., Maroof A.M., Merkle F.T., Koszka K., Intoh A., Armstrong I., Moccia R., Davis-Dusenbery B.N., Eggan K. The mouse C9ORF72 ortholog is enriched in neurons known to degenerate in ALS and FTD. Nat. Neurosci. 2013, 16:1725-1727.
45. Therrien M., Rouleau G.A., Dion P.A., Parker J.A. Deletion of C9ORF72 results in motor neuron degeneration and stress sensitivity in C. elegans. PLoS ONE 2013, 8:e83450.
46. Thompson P.M., Vinters H.V. Pathologic lesions in neurodegenerative disease. Molecular Biology of Neurodegenerative Diseases D 2012, 1-33. Elsevier. B. Teplow (Ed.).
47. Turner M.R., Scaber J., Goodfellow J.A., Lord M.E., Marsden R., Talbot K. The diagnostic pathway and prognosis in bulbar-onset amyotrophic lateral sclerosis. J. Neurol. Sci. 2010, 294:81-85.
48. Wen X., Tan W., Westergard T., Krishnamurthy K., Markandaiah S.S., Shi Y., Lin S., Shneider N.A., Monaghan J., Pandey U.B., et al. Antisense proline-arginine RAN dipeptides linked to C9ORF72-ALS/FTD form toxic nuclear aggregates that initiate in vitro and in vivo neuronal death. Neuron 2014, 84:1213-1225.
49. Wheeler T.M., Leger A.J., Pandey S.K., MacLeod A.R., Nakamori M., Cheng S.H., Wentworth B.M., Bennett C.F., Thornton C.A. Targeting nuclear RNA for in vivo correction of myotonic dystrophy. Nature 2012, 488:111-115.
50. Whitwell J.L., Weigand S.D., Boeve B.F., Senjem M.L., Gunter J.L., DeJesus-Hernandez M., Rutherford N.J., Baker M., Knopman D.S., Wszolek Z.K., et al. Neuroimaging signatures of frontotemporal dementia genetics: C9ORF72, tau, progranulin and sporadics. Brain 2012, 135:794-806.
51. Yokoyama J.S., Rosen H.J. Neuroimaging features of C9ORF72 expansion. Alzheimers Res. Ther. 2012, 4:45.
52. Zhang K., Donnelly C.J., Haeusler A.R., Grima J.C., Machamer J.B., Steinwald P., Daley E.L., Miller S.J., Cunningham K.M., Vidensky S., et al. The C9orf72 repeat expansion disrupts nucleocytoplasmic transport. Nature 2015, 525:56-61.
53. Zu T., Gibbens B., Doty N.S., Gomes-Pereira M., Huguet A., Stone M.D., Margolis J., Peterson M., Markowski T.W., Ingram M.A., et al. Non-ATG-initiated translation directed by microsatellite expansions. Proc. Natl. Acad. Sci. USA 2011, 108:260-265.
54. Zu T., Liu Y., Bañez-Coronel M., Reid T., Pletnikova O., Lewis J., Miller T.M., Harms M.B., Falchook A.E., Subramony S.H., et al. RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia. Proc. Natl. Acad. Sci. USA 2013, 110:E4968-E4977.